PDF(444 KB)
Research progress in application of inflammatory markers in diagnosis and treatment of coronary heart disease
Xiaoyu WANG,Bing LI,Guohui LIU
PDF(444 KB)
PDF(444 KB)
Research progress in application of inflammatory markers in diagnosis and treatment of coronary heart disease
),Guohui LIU()The inflammatory response runs through the entire process of the onset and progression of coronary atherosclerotic heart disease （CHD）； various inflammatory cells and inflammatory factors are involved， and to a certain extent， determine the stability of coronary atherosclerotic plaques and the progression of the disease. Lipoprotein（a） ［Lp（a）］， C-reactive protein （CRP）， neutrophils， platelets， and monocytes participate in the inflammatory response through various mechanisms such as inducing inflammatory factors， stimulating inflammatory cells， and secreting active substances， thus promoting the atherosclerosis. In contrast， the lymphocytes， as important immune cells， serve as the indicators of anti-inflammation. High-density lipoprotein cholesterol （HDL-C） exerts its anti-atherosclerotic effects by reversing cholesterol transport and inhibiting the aggregation of the inflammatory cells. In recent years， novel inflammatory markers composed of the aforementioned inflammation-related indicators have been closely related to the onset and progression of CHD and have significant guiding value in the diagnosis， treatment， and prognosis of CHD. Reducing inflammation remains a hotspot in current CHD research. The study analyzes the mechanism of promoting the CHD development by new inflammatory markers and reviews the therapeutic advancements targeting these relevant inflammatory markers， and provides the basis for the diagnosis and treatment of CHD.
Atherosclerosis / Coronary heart disease / Inflammation / Marker
R541.4
| 1 | PE?A-DUQUE M A， ROMERO-IBARRA J L， GAXIOLA-MACíAS M B， et al. Coronary atherosclerosis and interventional cardiology［J］. Arch Med Res， 2015， 46（5）： 372-378. |
| 2 | KHAN M A， HASHIM M J， MUSTAFA H， et al. Global epidemiology of ischemic heart disease： results from the global burden of disease study［J］. Cureus， 2020， 12（7）： e9349. |
| 3 | DURLACH V， BONNEFONT-ROUSSELOT D， BOCCARA F， et al. Lipoprotein（a）： Pathophysiology， measurement， indication and treatment in cardiovascular disease. A consensus statement from the Nouvelle Société Francophone d’Athérosclérose （NSFA）［J］. Arch Cardiovasc Dis， 2021， 114（12）： 828-847. |
| 4 | LAMPSAS S， XENOU M， OIKONOMOU E， et al. Lipoprotein（a） in atherosclerotic diseases： from pathophysiology to diagnosis and treatment［J］. Molecules， 2023， 28（3）： 969. |
| 5 | SHIM Y S， BAEK J W， KANG M J， et al. Reference values for the triglyceride to high-density lipoprotein cholesterol ratio and non-high-density lipoprotein cholesterol in Korean children and adolescents： the Korean national health and nutrition examination surveys 2007-2013［J］. J Atheroscler Thromb， 2016， 23（12）： 1334-1344. |
| 6 | FAN Y， HU J S， GUO F， et al. Lipoprotein（a） as a predictor of poor collateral circulation in patients with chronic stable coronary heart disease［J］. Rev Bras De Pesquisas Med E Biol， 2017， 50（8）： e5979. |
| 7 | HANIF S， AKHTAR B， AFZAL M N. Serum Lipoprotein （a） levels in acute coronary syndrome； Comparison of younger and elderly patients with healthy controls［J］. Pak J Med Sci， 2019， 35（6）： 1718-1723. |
| 8 | KAMSTRUP P R， BENN M， TYBJAERG-HANSEN A， et al. Extreme lipoprotein（a） levels and risk of myocardial infarction in the general population： the Copenhagen City Heart Study［J］. Circulation， 2008， 117（2）： 176-184. |
| 9 | QIN S Y， LIU J， JIANG H X， et al. Association between baseline lipoprotein （a） levels and restenosis after coronary stenting： meta-analysis of 9 cohort studies［J］. Atherosclerosis， 2013， 227（2）： 360-366. |
| 10 | KIMURA T， AKAHORI H， TANAKA T， et al. Impact of lipoprotein （a） on long-term outcome after percutaneous coronary intervention in the era of new generation drug-eluting stents［J］. J Cardiol， 2022， 80（2）： 179-183. |
| 11 | NICHOLLS S J， DITMARSCH M， KASTELEIN J J， et al. Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins： a randomized phase 2 trial［J］. Nat Med， 2022， 28（8）： 1672-1678. |
| 12 | GENCER B， MACH F. Potential of lipoprotein（a）- lowering strategies in treating coronary artery disease［J］. Drugs， 2020， 80（3）： 229-239. |
| 13 | O’DONOGHUE M L， KNUSEL B， et al. Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN（a） reduction-DOSE finding study （OCEAN（a）-DOSE）［J］. Am Heart J， 2022， 251： 61-69. |
| 14 | LAMB Y N. Inclisiran： first approval［J］. Drugs， 2021， 81（3）： 389-395. |
| 15 | MATSUSHITA K， HIBI K， KOMURA N， et al. Impact of serum lipoprotein （a） level on coronary plaque progression and cardiovascular events in statin-treated patients with acute coronary syndrome： a yokohama-acs substudy［J］. J Cardiol， 2020， 76（1）： 66-72. |
| 16 | CESARO A， SCHIAVO A， MOSCARELLA E， et al. Lipoprotein（a）： a genetic marker for cardiovascular disease and target for emerging therapies［J］. J Cardiovasc Med， 2021， 22（3）： 151-161. |
| 17 | DUARTE LAU F， GIUGLIANO R P. Lipoprotein（a） and its significance in cardiovascular disease： a review［J］. JAMA Cardiol， 2022， 7（7）： 760-769. |
| 18 | REHBERGER LIKOZAR A， ZAVRTANIK M， ?EBE?TJEN M. Lipoprotein（a） in atherosclerosis： from pathophysiology to clinical relevance and treatment options［J］. Ann Med， 2020， 52（5）： 162-177. |
| 19 | UELAND T， KLEVELAND O， MICHELSEN A E， et al. Serum lipoprotein（a） is not modified by interleukin-6 receptor antagonism or associated with inflammation in non-ST-elevation myocardial infarction［J］. Int J Cardiol， 2019， 274： 348-350. |
| 20 | SHEWMON D A， STOCK J L， ROSEN C J， et al. Tamoxifen and estrogen lower circulating lipoprotein（a） concentrations in healthy postmenopausal women［J］. Arterioscler Thromb， 1994， 14（10）： 1586-1593. |
| 21 | FARZAM K， SENTHILKUMARAN S. Lipoprotein A ［M］. Treasure Island （FL）： StatPearls Publishing， 2023. |
| 22 | SAHEBKAR A， SIMENTAL-MENDíA L E， STEFANUTTI C， et al. Supplementation with coenzyme Q10 reduces plasma lipoprotein（a） concentrations but not other lipid indices： a systematic review and meta-analysis［J］. Pharmacol Res， 2016， 105： 198-209. |
| 23 | YU C， CHEN M， CHEN Z， et al. Predictive and prognostic value of admission neutrophil-to-lymphocyte ratio in patients with CHD［J］. Herz， 2016， 41（7）： 605-613. |
| 24 | AGARWAL R， AURORA R G， SISWANTO B B， et al. The prognostic value of neutrophil-to-lymphocyte ratio across all stages of coronary artery disease［J］. Coron Artery Dis， 2022， 33（2）： 137-143. |
| 25 | YANG Y， XU Y N， WANG J， et al. Predictive efficacy of neutrophil-to-lymphocyte ratio for long-term prognosis in new onset acute coronary syndrome： a retrospective cohort study［J］. BMC Cardiovasc Disord， 2020， 20（1）： 500. |
| 26 | PAPA A， EMDIN M， PASSINO C， et al. Predictive value of elevated neutrophil-lymphocyte ratio on cardiac mortality in patients with stable coronary artery disease［J］. Clin Chim Acta， 2008， 395（1/2）： 27-31. |
| 27 | TAHTO E， JADRIC R， POJSKIC L， et al. Neutrophil-to-lymphocyte ratio and its relation with markers of inflammation and myocardial necrosis in patients with acute coronary syndrome［J］. Med Arch， 2017， 71（5）： 312-315. |
| 28 | MADJID M， AWAN I， WILLERSON J T， et al. Leukocyte count and coronary heart disease： implications for risk assessment［J］. J Am Coll Cardiol， 2004， 44（10）： 1945-1956. |
| 29 | BOAG S E， DAS R， SHMELEVA E V， et al. T lymphocytes and fractalkine contribute to myocardial ischemia/reperfusion injury in patients［J］. J Clin Invest， 2015， 125（8）： 3063-3076. |
| 30 | KARATA? M B， ?ANGA Y， ?PEK G， et al. Association of admission serum laboratory parameters with new-onset atrial fibrillation after a primary percutaneous coronary intervention［J］. Coron Artery Dis， 2016， 27（2）： 128-134. |
| 31 | RIDKER P M， EVERETT B M， THUREN T， et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease［J］. N Engl J Med， 2017， 377（12）： 1119-1131. |
| 32 | ADAMSTEIN N H， CORNEL J H， DAVIDSON M， et al. Association of interleukin 6 inhibition with ziltivekimab and the neutrophil-lymphocyte ratio： a secondary analysis of the RESCUE clinical trial［J］. JAMA Cardiol， 2023， 8（2）： 177-181. |
| 33 | ADAMSTEIN N H， MACFADYEN J G， ROSE L M， et al. The neutrophil-lymphocyte ratio and incident atherosclerotic events： analyses from five contemporary randomized trials［J］. Eur Heart J， 2021， 42（9）： 896-903. |
| 34 | ADALI M K， BUBER I， KILIC O， et al. Ticagrelor improves systemic immune-inflammation index in acute coronary syndrome patients［J］. Acta Cardiol， 2022， 77（7）： 632-638. |
| 35 | TANI S， MATSUO R， ATSUMI W， et al. Higher frequency of fish intake may be associated with a lower neutrophil/lymphocyte ratio： anti-atherosclerotic effects of fish consumption［J］. Ann Nutr Metab， 2021， 77（3）： 146-153. |
| 36 | AKBAS E M， GUNGOR A， OZCICEK A， et al. Vitamin D and inflammation： evaluation with neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio［J］. Arch Med Sci， 2016， 12（4）： 721-727. |
| 37 | FORDJOUR P A， WANG Y D， SHI Y， et al. Possible mechanisms of C-reactive protein mediated acute myocardial infarction［J］. Eur J Pharmacol， 2015， 760： 72-80. |
| 38 | OPRESCU N， MICHEU M M， SCAFA-UDRISTE A， et al. Inflammatory markers in acute myocardial infarction and the correlation with the severity of coronary heart disese［J］. Ann Med， 2021， 53（1）： 1041-1047. |
| 39 | LIUZZO G， BIASUCCI L M， GALLIMORE J R， et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina［J］. N Engl J Med， 1994， 331（7）： 417-424. |
| 40 | BOHULA E A， GIUGLIANO R P， LEITER L A， et al. Inflammatory and cholesterol risk in the FOURIER trial［J］. Circulation， 2018， 138（2）： 131-140. |
| 41 | SABATINE M S， MORROW D A， DE LEMOS J A， et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes： simultaneous assessment of troponin I， C-reactive protein， and B-type natriuretic peptide［J］. Circulation， 2002， 105（15）： 1760-1763. |
| 42 | RIDKER P M， CANNON C P， MORROW D， et al. C-reactive protein levels and outcomes after statin therapy［J］. N Engl J Med， 2005， 352（1）： 20-28. |
| 43 | MORROW D A， DE LEMOS J A， SABATINE M S， et al. Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial［J］. Circulation， 2006， 114（4）： 281-288. |
| 44 | ZHANG J， WANG X Y， TIAN W D， et al. The effect of various types and doses of statins on C-reactive protein levels in patients with dyslipidemia or coronary heart disease： a systematic review and network meta-analysis［J］. Front Cardiovasc Med， 2022， 9： 936817. |
| 45 | BALK E M， LAU J， GOUDAS L C， et al. Effects of statins on nonlipid serum markers associated with cardiovascular disease： a systematic review［J］. Ann Intern Med， 2003， 139（8）： 670-682. |
| 46 | NIDORF M， THOMPSON P L. Effect of colchicine （0.5 mg twice daily） on high-sensitivity C-reactive protein independent of aspirin and atorvastatin in patients with stable coronary artery disease［J］. Am J Cardiol， 2007， 99（6）： 805-807. |
| 47 | AIMO A， PASCUAL FIGAL D A， BAYES-GENIS A， et al. Effect of low-dose colchicine in acute and chronic coronary syndromes： a systematic review and meta-analysis［J］. Eur J Clin Invest， 2021， 51（4）： e13464. |
| 48 | RIDKER P M， DEVALARAJA M， BAERES F M M， et al. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk （RESCUE）： a double-blind， randomised， placebo-controlled， phase 2 trial［J］. Lancet， 2021， 397（10289）： 2060-2069. |
| 49 | WADA Y， JENSEN C， MEYER A S P， et al. Efficacy and safety of interleukin-6 inhibition with ziltivekimab in patients at high risk of atherosclerotic events in Japan （RESCUE-2）： a randomized， double-blind， placebo-controlled， phase 2 trial［J］. J Cardiol， 2023， 82（4）： 279-285. |
| 50 | PEPYS M B， HIRSCHFIELD G M， TENNENT G A， et al. Targeting C-reactive protein for the treatment of cardiovascular disease［J］. Nature， 2006， 440（7088）： 1217-1221. |
| 51 | IKONOMIDIS I， ANDREOTTI F， ECONOMOU E， et al. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin［J］. Circulation， 1999， 100（8）： 793-798. |
| 52 | TAKEDA T， HOSHIDA S， NISHINO M， et al. Relationship between effects of statins， aspirin and angiotensin II modulators on high-sensitive C-reactive protein levels［J］. Atherosclerosis， 2003， 169（1）： 155-158. |
| 53 | TEMIZ A， GAZI E， GUNGOR O， et al. Platelet/lymphocyte ratio and risk of in-hospital mortality in patients with ST-elevated myocardial infarction［J］. Med Sci Monit， 2014， 20： 660-665. |
| 54 | AKDAG S， AKYOL A， ASKER M， et al. The relation of platelet-lymphocyte ratio and coronary collateral circulation in patients with non-ST segment elevation myocardial infarction［J］. Adv Interv Cardiol， 2016， 12（3）： 224-230. |
| 55 | 石红宾， 李中南， 陈明月， 等. 2型糖尿病合并痛风性关节炎患者单核细胞高密度脂蛋白胆固醇比值与非酒精性脂肪肝关系研究［J］. 中国实用内科杂志， 2024， 44（5）： 397-402. |
| 56 | ZHANG M H， WU S H， XU S， et al. Impact of monocyte to high-density lipoprotein ratio on the identification of prevalent coronary heart disease： insights from a general population［J］. Postgrad Med， 2021， 133（7）： 822-829. |
| 57 | BALTA S， CELIK T， OZTURK C， et al. The relation between monocyte to HDL ratio and no-reflow phenomenon in the patients with acute ST-segment elevation myocardial infarction［J］. Am J Emerg Med， 2016， 34（8）： 1542-1547. |
| 58 | CANPOLAT U， ?ETIN E H， CETIN S， et al. Association of monocyte-to-HDL cholesterol ratio with slow coronary flow is linked to systemic inflammation［J］. Clin Appl Thromb Hemost， 2016， 22（5）： 476-482. |
| 59 | JI H H， LI Y， FAN Z Y， et al. Monocyte/lymphocyte ratio predicts the severity of coronary artery disease： a syntax score assessment［J］. BMC Cardiovasc Disord， 2017， 17（1）： 90. |
| 60 | FAN Z Y， JI H H， LI Y， et al. Relationship between monocyte-to-lymphocyte ratio and coronary plaque vulnerability in patients with stable angina［J］. Biomark Med， 2017， 11（11）： 979-990. |
/
| 〈 |
|
〉 |
AI Summary
